ALQ – Macquarie rates the stock as Outperform
The Outperform rating is retained and the target price increases to $14.70 from $14.00.
Read MoreTag: ALQ
ALQ – Credit Suisse rates the stock as Outperform
Credit Suisse has raised its FY22 EPS forecast by 2.6% and increases the target price to $15.05 from $14.07. Outperform.
Read MoreALQ – Credit Suisse rates the stock as Outperform
The Outperform rating is retained and the target price increases to $14.70 from $14.10.
Read MoreALS Shares the Wealth from Bumper Half
ALS will pay a sharply higher dividend for the September half, with the Brisbane-based testing group boosting underlying net profit more than 57% and seeing more of the same moving forward.
Read MoreALQ – Morgans rates the stock as Hold
Morgans raises the target to $13.17 from $12.45 and retains a Hold rating.
Read MoreALQ – Macquarie rates the stock as Outperform
Outperform rating maintained. Target is $13.80.
Read MoreALQ – UBS rates the stock as Neutral
UBS retains a Neutral rating and raises the target to $13.00 from $12.25.
Read MoreALQ – Credit Suisse rates the stock as Outperform
Credit Suisse retains an Outperform rating and increases the target to $13.45 from $10.40.
Read MoreALS Surges on Higher Earnings, Dividend
Shares in global testing lab operator ALS surged more than 12% yesterday to a new year’s high as the company played catch up for its shareholders with a sharply higher final payout.
Read MoreLift In Exploration Augurs Well For ALS
As the outlook for minerals exploration improves and concerns over the economic impact of the pandemic ease, the laboratory services of ALS Ltd will be in demand.
Read MoreALQ – UBS rates the stock as Neutral
ALS Ltd will acquire Investiga, a pharmaceutical testing company based in the Americas. UBS retains a Neutral rating and $9.90 target and believes the stock adequately prices in the global improvement.
Read MoreALS Talks Up Prospects, Makes Acquisition
An upbeat trading update for the six months to March 31 from Brisbane-based global testing group ALS came with news of a small acquisition in Brazil.
Read MoreALS To Benefit As Mineral Exploration Heats Up
ALS has invested in additional geochemistry capacity as the cycle for global mineral exploration ramps up again, providing an improved earnings outlook.
Read MoreTesting Group ALS Cuts Dividend As Profit Halves
Testing and inspection business ALS has chopped interim dividend by a quarter after its first-half result produced lower revenue and earnings, with more of the same to come.
Read MoreALQ – UBS rates the stock as Neutral
ALS’s first-quarter revenues were down -10% versus the June quarter due to covid-19 restrictions.
Read MoreALQ – Morgan Stanley rates the stock as Overweight
Morgan Stanley notes while ALS has lagged its global peers over the last 1-2 years, there is upside potential for if the expansion of its Life Sciences business continues.
Read MoreALQ – Macquarie rates the stock as Outperform
The broker notes lead indicators for ALS’ geochem business are improving, with Canadian resource raisings up 66% in the first half of 2020 and Australian raisings also lifting off low levels. Typically there is a 2-3 month lag for resource raisings to flow into additional exploration activity.
Read MoreALS Poised For Recovery
ALS Ltd has acted quickly to manage the economic downturn but a robust recovery in sample flows and testing is expected as lockdowns measures are unwound.
Read MoreALQ – UBS rates the stock as Neutral
FY20 net profit was slightly ahead of UBS estimates. The company has reiterated recent commentary regarding trading and provided no formal FY21 guidance.
Read MoreOne-Offs Mask Weaker Result At ALS
Shares in Brisbane-based global testing group, ALS Ltd rose nearly 3% despite the group revealing a weak 2019-20 result and lower final dividend.
Read MoreSouth32, Woodside, ALS All Batten Down The Hatches
Woodside Petroleum is bracing for “unprecedented circumstances”, global testing giant ALS is marshaling its financial forces to survive the impact of COVID-19 while South32 plans slash capital expenditure and has suspended its on-market buyback.
Read MoreALS Shares Shoot Higher On “Pleasing Result”
Brisbane-based multinational testing group, ALS saw its shares buck what was a very, very weak market yesterday after reporting better than forecast half-year earnings, a higher dividend and an upbeat earnings forecast for the year to next March.
Read MoreALQ – Credit Suisse rates the stock as Downgrade to Neutral from Outperform
While the stock is priced for a recovery in geochemistry Credit Suisse finds little evidence this is occurring. The focus at the result is likely to be on the volume growth in geochemistry and continued margin improvement in life sciences.
Read MoreMining Services Companies Follow The Major Miners
A collection of mining services companies beginning to experience some attractive breakouts that point to these flow-on affects from mining activity translating to a sustained increase in earnings.
Read MoreALQ – Morgans rates the stock as Hold
The first half guidance issued at the AGM was slightly below Morgans’ expectations. The broker believes peak commodities-driven growth is now behind the company and the health of the exploration and mining capital raisings remain key to the performance in FY20.
Read MoreALQ – Credit Suisse rates the stock as Neutral
FY19 net profit was in line with Credit Suisse estimates. Revenue growth occurred across all segments and margins improved in life sciences for the first time in six years.
Read MoreALS Outlook Tests Shareholder Resolve
A good result from Brisbane-based global testing group ALS yesterday with 27.3% lift in after-tax net profit to $181 million for the 2018-19 year ending March 31.
Read MoreALQ – Macquarie rates the stock as Outperform
Macquarie expects earnings growth will prove to be robust when the company reports its FY19 result on May 21. Life Sciences produced strong sequential improvement in the first half and the broker expects a margin expansion of 130 basis points in the second half.
Read MoreALS Limited Rides Resources Rebound
The rebound in global resources and in the wider economy has seen the Brisbane-based global testing giant, ALS Limited boost interim dividend by a third after lifting earnings by 30% on an underlying basis to $93.3 million for the September half of its 2018-19 financial year.
Read MoreEarnings Turnaround Sees ALS Test Positive For Growth
Shares in Brisbane-based global testing giant, ALS Ltd surged yesterday, adding more than 11% in value after the company’s annual meeting heard an upbeat outlook for the first half of the 2018-19 financial year.
Read MoreALS Ups Dividend On Solid Result
Brisbane-based testing group, ALS Ltd has lifted final dividend on top of a higher interim after reporting an improved underlying performance for 2017-18.
Read MoreALS Soothes Investor Concerns
You can understand why Brisbane-based testing group, ALS Limited will offer shareholders a $175 million buy back, as well as a higher interim dividend after announcing an underlying net profit after tax of $70.1 million for the six months to September 30, 2017. While the company reported a solid underlying result, the after tax result including one offs saw the impact of more impairments on its assets – this time in its coal testing division.
Read MoreALS Rides Resources Rebound
Shares in Brisbane based testing group ALS jumped nearly 12% as investors reacted favourably to the release of the 216-17 results late on Tuesday night.
Read MoreALS Warns Earnings Yet To Bottom
The news wasn’t encouraging yesterday for shareholders in Brisbane-based testing giant, ALS (ALQ), which only a month and a bit ago rejected an unwanted $2.7 billion takeover approach.
Read MoreALS Rejects ‘Opportunistic’ Bid
Is the takeover offer for ALS a replay of Treasury Wine Estates and the way it fought off numerous approaches from private equity groups trying to buy the company before a turnaround became apparent – a rebound that has seen Treasury shares double from the original offer price?
Read MorePrivate Equity Stalks ALS
Another global Australian company is under takeover threat.
Read MoreTesting Outlook For ALS
Brisbane-based testing group ALS Ltd (ALQ) saw its shares hammered more than 11% lower yesterday as investors gave the full year results and weak outlook the thumbs down.
Read MoreALS Managing Slowdown
Shares in testing giant ALS (ALQ) shook off a small first half downgrade revealed at yesterday’s annual meeting in Brisbane to close up more than 3%.
Read MoreRestructuring ALS Posts $174.5m Loss
Brisbane-based testing services group ALS Limited (ALQ) is not letting the downturn in the mining, oil and gas and other areas of the economy (such as water) and a loss in 2014-15 stop it from continuing on its growth plan.
Read More